Abstract
Chronic pancreatitis (CP) is a persistent inflammation of the pancreas that disrupts normal structure and functions. The absence of well-defined criteria for early diagnosis of CP and the multi-factorial features of the disease render it difficult to develop an effective treatment. Stem cell therapy has emerged as a promising therapy for autoimmune diseases and may represent a therapeutic option for CP treatment. In this issue of Molecular Therapy, Sun et al.1 report that the infusion of adipose-derived mesenchymal stem cells (ASCs) into an experimental murine model of CP inhibited the progression of CP, greatly attenuated pancreatic damage, and reduced fibrosis and cell death.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
